Evidence map›Paper›PMID 35260634›Full record

ArticleScientific reports2022

Computing microRNA-gene interaction networks in pan-cancer using miRDriver.

Banabithi Bose, Matthew Moravec, Serdar Bozdag

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Banabithi BoseCenter for Genetic Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA. banabithi.bose@northwestern.edu.
Matthew MoravecDepartment of Mathematical and Statistical Sciences, Marquette University, Milwaukee, WI, 53201, USA.
Serdar BozdagDepartment of Computer Science and Engineering, University of North Texas, Denton, TX, 76203, USA. serdar.bozdag@unt.edu.

Funding

lntegrating multi-omics datasets to infer phenotype-specific driver genes, regulatory interactions and drug responseR35GM133657 · NIGMS · UNIVERSITY OF NORTH TEXAS · PI Serdar Bozdag · 2019 to 2026
$3.1M
NIGMS NIH HHS R35 GM133657
6 · The paper itself

Abstract

DNA copy number aberrated regions in cancer are known to harbor cancer driver genes and the short non-coding RNA molecules, i.e., microRNAs. In this study, we integrated the multi-omics datasets such as copy number aberration, DNA methylation, gene and microRNA expression to identify the signature microRNA-gene associations from frequently aberrated DNA regions across pan-cancer utilizing a LASSO-based regression approach. We studied 7294 patient samples associated with eighteen different cancer types from The Cancer Genome Atlas (TCGA) database and identified several cancer-specific and common microRNA-gene interactions enriched in experimentally validated microRNA-target interactions. We highlighted several oncogenic and tumor suppressor microRNAs that were cancer-specific and common in several cancer types. Our method substantially outperformed the five state-of-art methods in selecting significantly known microRNA-gene interactions in multiple cancer types. Several microRNAs and genes were found to be associated with tumor survival and progression. Selected target genes were found to be significantly enriched in cancer-related pathways, cancer hallmark and Gene Ontology (GO) terms. Furthermore, subtype-specific potential gene signatures were discovered in multiple cancer types.

Indexed as

MicroRNAsNeoplasmsDNA MethylationGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansOncogenesMicroRNAs

Identifiers

PMID35260634
PMCPMC8904490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.